Skip to main content
Top
Published in: Supportive Care in Cancer 4/2004

01-04-2004 | Review Article

The economic burden of supportive care of cancer patients

Authors: Linda S. Elting, Ya-Chen Tina Shih

Published in: Supportive Care in Cancer | Issue 4/2004

Login to get access

Abstract

Goals of work

Economic and regulatory healthcare policy is limited by the lack of population-based information on the cost of supportive care of cancer patients. The goal of this study was to estimate these costs and to explore the impact of these costs on policy decisions.

Patients and methods

We identified estimates of the cost of outpatient and inpatient supportive care from published reports in the literature. The range of these costs (from lowest to highest) is described for each supportive care condition. These estimates were supplemented by computing the cost of all hospitalizations for these conditions in Texas between June 2000 and December 2001. Medicare payments were used to estimate average reimbursement. Costs (not charges) were standardized to 2002 US dollars using the consumer price index for medical care and Medicare’s cost-to-charge ratio for Texas.

Main results

Inpatient care for most conditions exceeded $7000 per episode. Our population-based estimates of the cost of care were similar to literature-based estimates, except in the case where conditions could be managed in the outpatient setting. Average Medicare payments were often far lower than the estimated cost of care. For example, the estimated cost of hospitalization for management of diarrhea was $6616 while the average Medicare payment was only $2809.

Conclusions

Many supportive care interventions are quite expensive. In an environment focused on cost containment, a risk-based approach to expensive supportive care treatments is essential. Further study of the cost effectiveness of supportive care management strategies is indicated.
Literature
1.
go back to reference Ackerman SJ, Klumpp TR, Guzman GI, et al (2000) Economic consequences of alterations in platelet transfusion dose: analysis of a prospective, randomized, double-blind trial. Transfusion 40:1457–1462CrossRefPubMed Ackerman SJ, Klumpp TR, Guzman GI, et al (2000) Economic consequences of alterations in platelet transfusion dose: analysis of a prospective, randomized, double-blind trial. Transfusion 40:1457–1462CrossRefPubMed
2.
go back to reference Attanasio E, Russo P, Carunchio G, Caprino L (2001) Dematan sulfate versus unfractionated heparin for the prevention of venous thromboembolism in patients undergoing surgery for cancer: a cost-effectiveness analysis. Pharmacoeconomics 19:57–68 Attanasio E, Russo P, Carunchio G, Caprino L (2001) Dematan sulfate versus unfractionated heparin for the prevention of venous thromboembolism in patients undergoing surgery for cancer: a cost-effectiveness analysis. Pharmacoeconomics 19:57–68
3.
go back to reference Bank of Canada (2003) http://www.bank-banque-canada.ca/pdf/nraa98.pdf Bank of Canada (2003) http://​www.​bank-banque-canada.​ca/​pdf/​nraa98.​pdf
4.
go back to reference Barosi G, Marchetti M, Liberato NL (1998) Cost-effectiveness of recombinant human erythropoietin in the prevention of chemotherapy-induced anaemia. Br J Cancer 78:781–787PubMed Barosi G, Marchetti M, Liberato NL (1998) Cost-effectiveness of recombinant human erythropoietin in the prevention of chemotherapy-induced anaemia. Br J Cancer 78:781–787PubMed
5.
go back to reference Bennett CL, Weeks JA, Somerfield MR, Feinglass J, Smith TJ (1999) Use of hematopoietic colony-stimulating factors: comparison of the 1994 and 1997 American Society of Clinical Oncology surveys regarding ASCO clinical practice guidelines. J Clin Oncol 17:3676–3681PubMed Bennett CL, Weeks JA, Somerfield MR, Feinglass J, Smith TJ (1999) Use of hematopoietic colony-stimulating factors: comparison of the 1994 and 1997 American Society of Clinical Oncology surveys regarding ASCO clinical practice guidelines. J Clin Oncol 17:3676–3681PubMed
6.
go back to reference Adams JR, Elting LS, Lyman GH, George JN, Lembersky BC, Armitage JO, Demetri GD, Bennett CL (2004) Use of erythropoietin in cancer patients: assessment of oncologists’ practice patterns in the United States and other countries. Am J Med 116:28–34CrossRefPubMed Adams JR, Elting LS, Lyman GH, George JN, Lembersky BC, Armitage JO, Demetri GD, Bennett CL (2004) Use of erythropoietin in cancer patients: assessment of oncologists’ practice patterns in the United States and other countries. Am J Med 116:28–34CrossRefPubMed
7.
go back to reference Bureau of Labor Statistics (2003) Consumer price index – medical care. US Department of Labor. http://www.bls.gov Bureau of Labor Statistics (2003) Consumer price index – medical care. US Department of Labor. http://​www.​bls.​gov
8.
go back to reference Calhoun EA, Chang CH, Welshman EE, Fishman DA, Lurain JR, Bennet CL (2001) Evaluating the total costs of chemotherapy-induced toxicity: results from a pilot study with ovarian cancer patients. Oncologist 6:441–444PubMed Calhoun EA, Chang CH, Welshman EE, Fishman DA, Lurain JR, Bennet CL (2001) Evaluating the total costs of chemotherapy-induced toxicity: results from a pilot study with ovarian cancer patients. Oncologist 6:441–444PubMed
9.
go back to reference Cantor SB, Rubenstein EB, Elting LS, Frisbee-Hume S, Bratka CS, Stedman D, Rolston KVI (1997) Economic evaluation of management strategies for low-risk febrile neutropenic cancer patients. J Clin Oncol 16:419a Cantor SB, Rubenstein EB, Elting LS, Frisbee-Hume S, Bratka CS, Stedman D, Rolston KVI (1997) Economic evaluation of management strategies for low-risk febrile neutropenic cancer patients. J Clin Oncol 16:419a
10.
go back to reference Caro JJ, Getsios D, Caro I, O’Brien JA (2002) Cost effectiveness of tinzaparin sodium versus unfractionated heparin in the treatment of proximal deep vein thrombosis. Pharmacoeconomics 20:593–602PubMed Caro JJ, Getsios D, Caro I, O’Brien JA (2002) Cost effectiveness of tinzaparin sodium versus unfractionated heparin in the treatment of proximal deep vein thrombosis. Pharmacoeconomics 20:593–602PubMed
11.
go back to reference Castagnola E, Paola D, Giacchino R, Rossi R, Viscoli C (1998) Economic aspects of empiric antibiotic therapy for febrile neutropenia in children with cancer. Support Care Cancer 6:524–528CrossRefPubMed Castagnola E, Paola D, Giacchino R, Rossi R, Viscoli C (1998) Economic aspects of empiric antibiotic therapy for febrile neutropenia in children with cancer. Support Care Cancer 6:524–528CrossRefPubMed
12.
go back to reference Chaplin S (1991) Cancer therapy complications costly to treat. Hosp Doctor 9:30 Chaplin S (1991) Cancer therapy complications costly to treat. Hosp Doctor 9:30
13.
go back to reference Chevat C, Peňa BM, Maiwenn JAL, Rutten FFH (2001) Healthcare resource utilization and costs of treating NSAID-associated gastrointestinal toxicity: a multinational perspective. Pharmacoeconomics 19 [Suppl 1]:17–32 Chevat C, Peňa BM, Maiwenn JAL, Rutten FFH (2001) Healthcare resource utilization and costs of treating NSAID-associated gastrointestinal toxicity: a multinational perspective. Pharmacoeconomics 19 [Suppl 1]:17–32
14.
go back to reference Comay D, Marshall JK (2002) Resource utilization for acute lower gastrointestinal hemorrhage: the Ontario GI bleed study. Can J Gastroenterol 16:677–682PubMed Comay D, Marshall JK (2002) Resource utilization for acute lower gastrointestinal hemorrhage: the Ontario GI bleed study. Can J Gastroenterol 16:677–682PubMed
15.
go back to reference Costa VC, Ferraz MB, Petrilli AS, Pereira CA, Rogerio JW (2003) Resource utilization and cost of episodes of febrile neutropenia in children with acute leukemias and lymphomas. Support Care Cancer 11:356–361PubMed Costa VC, Ferraz MB, Petrilli AS, Pereira CA, Rogerio JW (2003) Resource utilization and cost of episodes of febrile neutropenia in children with acute leukemias and lymphomas. Support Care Cancer 11:356–361PubMed
16.
go back to reference Dalton JD, Bailey NP, Barrett-Lee PJ, O’Brien MER (1998) Multicenter UK audit of anemia in patients receiving cytotoxic chemotherapy. Proc Am Soc Clin Oncol 17:418a Dalton JD, Bailey NP, Barrett-Lee PJ, O’Brien MER (1998) Multicenter UK audit of anemia in patients receiving cytotoxic chemotherapy. Proc Am Soc Clin Oncol 17:418a
17.
go back to reference Delea TE, Vera-Llonch M, Edelsberg JS, et al (2002) The incidence and cost of hospitalization for 5-FU toxicity among Medicare beneficiaries with metastatic colorectal cancer. Value Health 5:35–43CrossRefPubMed Delea TE, Vera-Llonch M, Edelsberg JS, et al (2002) The incidence and cost of hospitalization for 5-FU toxicity among Medicare beneficiaries with metastatic colorectal cancer. Value Health 5:35–43CrossRefPubMed
18.
go back to reference Dimick JB, Pronovost PJ, Cowan JA, Lipsett PA (2003) Complications and costs after high-risk surgery: where should we focus quality improvement initiatives? J Am Coll Surg 196:671–678CrossRefPubMed Dimick JB, Pronovost PJ, Cowan JA, Lipsett PA (2003) Complications and costs after high-risk surgery: where should we focus quality improvement initiatives? J Am Coll Surg 196:671–678CrossRefPubMed
19.
go back to reference Dranitsaris G, Tran MT, McGeer A, Narine L (1995) Pharmacoeconomic analysis of empirical therapy with ceftazidime alone or combination antibiotics for febrile neutropenia in cancer patients. Pharmacoeconomics 7:49–62PubMed Dranitsaris G, Tran MT, McGeer A, Narine L (1995) Pharmacoeconomic analysis of empirical therapy with ceftazidime alone or combination antibiotics for febrile neutropenia in cancer patients. Pharmacoeconomics 7:49–62PubMed
20.
go back to reference Drummond MF, Dubois D, Garattini L, et al (1999) Current trends in the use of pharmacoeconomics and outcomes research in Europe. Value Health 2:323–332CrossRef Drummond MF, Dubois D, Garattini L, et al (1999) Current trends in the use of pharmacoeconomics and outcomes research in Europe. Value Health 2:323–332CrossRef
21.
go back to reference Elting LS, Cantor SB (2002) Outcomes and costs of febrile neutropenia: adventures in the science and art of treatment choices. Supp Care Cancer 10:189–196CrossRef Elting LS, Cantor SB (2002) Outcomes and costs of febrile neutropenia: adventures in the science and art of treatment choices. Supp Care Cancer 10:189–196CrossRef
22.
go back to reference Elting L, Gupta S, Kurtin D, Martin C, Rivera E, Salama V, Escalante C (1999) Outcomes of deep venous thrombosis (DVT) in cancer patients. Arch Intern Med (in press) Elting L, Gupta S, Kurtin D, Martin C, Rivera E, Salama V, Escalante C (1999) Outcomes of deep venous thrombosis (DVT) in cancer patients. Arch Intern Med (in press)
23.
go back to reference Elting LS, Rubenstein EB, Martin CG, Kurtin D, Rodriguez S, Laiho E, Kanesan K, Cantor SB, Benjamin RS (2001) Incidence, cost and outcomes of bleeding and chemotherapy dose modification among solid tumor patients with chemotherapy-induced thrombocytopenia. J Clin Oncol 19:1137–1146PubMed Elting LS, Rubenstein EB, Martin CG, Kurtin D, Rodriguez S, Laiho E, Kanesan K, Cantor SB, Benjamin RS (2001) Incidence, cost and outcomes of bleeding and chemotherapy dose modification among solid tumor patients with chemotherapy-induced thrombocytopenia. J Clin Oncol 19:1137–1146PubMed
24.
go back to reference Elting LS, Cooksley C, Chambers M, Martin C, Manzullo, E, Rubenstein E (2002) Outcomes of oral mucositis among cancer patients (abstract 34). Supp Care Cancer 10:363 Elting LS, Cooksley C, Chambers M, Martin C, Manzullo, E, Rubenstein E (2002) Outcomes of oral mucositis among cancer patients (abstract 34). Supp Care Cancer 10:363
25.
go back to reference Elting LS, Cantor SB, Martin CG, Hamblin L, Kurtin D, Rivera E, Vadhan-Raj S, Benjamin RS (2003) Cost of chemotherapy-induced thrombocytopenia among patients with lymphoma or solid tumors. Cancer 97:1541–1550CrossRefPubMed Elting LS, Cantor SB, Martin CG, Hamblin L, Kurtin D, Rivera E, Vadhan-Raj S, Benjamin RS (2003) Cost of chemotherapy-induced thrombocytopenia among patients with lymphoma or solid tumors. Cancer 97:1541–1550CrossRefPubMed
26.
go back to reference Escalante CP, Kurtin D, Rivera E, Elting LS (2000) Severity of illness, outcomes and resource utilization in elderly cancer patients with deep venous thrombosis. Clin Appl Thromb Hemost 6:175–178PubMed Escalante CP, Kurtin D, Rivera E, Elting LS (2000) Severity of illness, outcomes and resource utilization in elderly cancer patients with deep venous thrombosis. Clin Appl Thromb Hemost 6:175–178PubMed
27.
go back to reference ExchangeRate.com Inc. (2003) www.exchangerate.com. Accessed 10 June 2003 ExchangeRate.com Inc. (2003) www.exchangerate.com. Accessed 10 June 2003
28.
go back to reference Forbes JM, Anderson GF, Anderson GC, Bleecker EC, Rossi EC, Moss GS (1991) Blood transfusion costs: a multicenter study. Transfusion 31:318–323CrossRefPubMed Forbes JM, Anderson GF, Anderson GC, Bleecker EC, Rossi EC, Moss GS (1991) Blood transfusion costs: a multicenter study. Transfusion 31:318–323CrossRefPubMed
29.
go back to reference Fortner BV, Okon TA, Portenoy RK (2002) A survey of pain-related hospitalizations, emergency department visits, and physician office visits reported by cancer patients with and without history of breakthrough pain. J Pain 3:38–44CrossRefPubMed Fortner BV, Okon TA, Portenoy RK (2002) A survey of pain-related hospitalizations, emergency department visits, and physician office visits reported by cancer patients with and without history of breakthrough pain. J Pain 3:38–44CrossRefPubMed
30.
go back to reference Garrelts JC, Horst WD, Silkey B, Gagnon S (1994) A pharmacoeconomic model to evaluate antibiotic costs. Pharmacotherapy 14:438–445PubMed Garrelts JC, Horst WD, Silkey B, Gagnon S (1994) A pharmacoeconomic model to evaluate antibiotic costs. Pharmacotherapy 14:438–445PubMed
31.
go back to reference Glaspy JA, Bleecker GC, Stoller RG, Strauss MJ (1991) Decreased costs in cancer chemotherapy patients using recombinant granulocyte colony-stimulating factor (abstract). Clin Res 39:7A Glaspy JA, Bleecker GC, Stoller RG, Strauss MJ (1991) Decreased costs in cancer chemotherapy patients using recombinant granulocyte colony-stimulating factor (abstract). Clin Res 39:7A
32.
go back to reference Greer M (2001) Blood transfusion most cost-effective option for anemia treatment. Blood Weekly 11/15 Greer M (2001) Blood transfusion most cost-effective option for anemia treatment. Blood Weekly 11/15
33.
go back to reference Haddix AC, Shaffer PA (1996) Cost-effectiveness analysis. In: Haddix AC, Teutsch SM, Shaffer PA, Dunet DO (eds) Prevention effectiveness: a guide to decision analysis and economic evaluation. Oxford University Press, New York Haddix AC, Shaffer PA (1996) Cost-effectiveness analysis. In: Haddix AC, Teutsch SM, Shaffer PA, Dunet DO (eds) Prevention effectiveness: a guide to decision analysis and economic evaluation. Oxford University Press, New York
34.
go back to reference Heckinger B, Lee J, Calhoun B, Bennett C (2003) The direct and indirect costs of febrile neutropenia: estimates based on community practice care in modern era. Proceedings American Society of Clinical Oncology Meeting, vol. 22 Heckinger B, Lee J, Calhoun B, Bennett C (2003) The direct and indirect costs of febrile neutropenia: estimates based on community practice care in modern era. Proceedings American Society of Clinical Oncology Meeting, vol. 22
35.
go back to reference Jefferies LC, Sachais BS, Young DS (2001) Blood transfusion costs by diagnosis-related groups in 60 university hospitals in 1995. Transfusion 41:522–529CrossRefPubMed Jefferies LC, Sachais BS, Young DS (2001) Blood transfusion costs by diagnosis-related groups in 60 university hospitals in 1995. Transfusion 41:522–529CrossRefPubMed
36.
go back to reference Kavanagh BD, Fischer BA, Segreti EM, Wheelock JB, et al (2001) Cost analysis of erythropoietin versus blood transfusions for cervical cancer patients receiving chemoradiotherapy. Int J Radiat Oncol Biol Phys 51:435–441CrossRefPubMed Kavanagh BD, Fischer BA, Segreti EM, Wheelock JB, et al (2001) Cost analysis of erythropoietin versus blood transfusions for cervical cancer patients receiving chemoradiotherapy. Int J Radiat Oncol Biol Phys 51:435–441CrossRefPubMed
37.
go back to reference Leese B (1993) The costs of treating febrile neutropenia in six UK hospitals. Eur J Cancer 29A [Suppl 7]:15–18 Leese B (1993) The costs of treating febrile neutropenia in six UK hospitals. Eur J Cancer 29A [Suppl 7]:15–18
38.
go back to reference Leese B (1994) The costs of treating febrile neutropenia in patients with malignant blood disorders. Pharmacoeconomics 6:233–239PubMed Leese B (1994) The costs of treating febrile neutropenia in patients with malignant blood disorders. Pharmacoeconomics 6:233–239PubMed
39.
go back to reference Levit K, Smith C, Cowan C, Lazenby H, Martin A (2002) Inflation spurs health spending in 2000. Health Affairs 21:172–181CrossRefPubMed Levit K, Smith C, Cowan C, Lazenby H, Martin A (2002) Inflation spurs health spending in 2000. Health Affairs 21:172–181CrossRefPubMed
40.
go back to reference Lyman GH, Kuderer N, Greene J, Balducci L (1998) The economics of febrile neutropenia: implications for the use of colony-stimulating factors. Eur J Cancer 34:1857–1864PubMed Lyman GH, Kuderer N, Greene J, Balducci L (1998) The economics of febrile neutropenia: implications for the use of colony-stimulating factors. Eur J Cancer 34:1857–1864PubMed
41.
go back to reference Maxwell GL, Myers ER, Clarke-Person C (2000) Cost-effectiveness of deep venous thrombosis prophylaxis in gynecologic oncology surgery. Obstet Gynecol 95:206–214CrossRefPubMed Maxwell GL, Myers ER, Clarke-Person C (2000) Cost-effectiveness of deep venous thrombosis prophylaxis in gynecologic oncology surgery. Obstet Gynecol 95:206–214CrossRefPubMed
42.
go back to reference Meadowcroft AM, Gilbert CJ, Maravich-May D, et al (1998) Cost of managing anemia with and without prophylactic epoetin alfa therapy in breast cancer patients receiving combination chemotherapy. Am J Health Syst Pharm 55:1898–1902PubMed Meadowcroft AM, Gilbert CJ, Maravich-May D, et al (1998) Cost of managing anemia with and without prophylactic epoetin alfa therapy in breast cancer patients receiving combination chemotherapy. Am J Health Syst Pharm 55:1898–1902PubMed
43.
go back to reference Meehan KR, Matias CO, Rathore SS, Sandler SG, Kallich J, LaBrecque J, Erder H, Schulman KA (2000) Platelet transfusions: utilization and associated costs in a tertiary care hospital. Am J Hematol 64:251–256CrossRefPubMed Meehan KR, Matias CO, Rathore SS, Sandler SG, Kallich J, LaBrecque J, Erder H, Schulman KA (2000) Platelet transfusions: utilization and associated costs in a tertiary care hospital. Am J Hematol 64:251–256CrossRefPubMed
44.
go back to reference Minotti V, Gentile G, Bucaneve G, et al (1999) Domiciliary treatment of febrile episodes in cancer patients: a prospective randomized trial comparing oral versus parenteral empirical antibiotic treatment. Support Care Cancer 7:134–139CrossRefPubMed Minotti V, Gentile G, Bucaneve G, et al (1999) Domiciliary treatment of febrile episodes in cancer patients: a prospective randomized trial comparing oral versus parenteral empirical antibiotic treatment. Support Care Cancer 7:134–139CrossRefPubMed
45.
go back to reference Monte ED, Belmont MJ, Wax MK (1999) Management paradigms for posterior epistaxis: a comparison of costs and complications. Otolaryngol Head Neck Surg 121:103–106PubMed Monte ED, Belmont MJ, Wax MK (1999) Management paradigms for posterior epistaxis: a comparison of costs and complications. Otolaryngol Head Neck Surg 121:103–106PubMed
46.
go back to reference Nuijten MJC, Berto P, Berdeaux G, et al (2001) Trends in decision-making process for pharmaceuticals in Western European countries. HEPAC 2:162–169CrossRef Nuijten MJC, Berto P, Berdeaux G, et al (2001) Trends in decision-making process for pharmaceuticals in Western European countries. HEPAC 2:162–169CrossRef
47.
go back to reference O’Brien JA, Caro J (2002) Direct medical cost of managing deep vein thrombosis according to the occurrence of complications. Pharmacoeconomics 20:603–615PubMed O’Brien JA, Caro J (2002) Direct medical cost of managing deep vein thrombosis according to the occurrence of complications. Pharmacoeconomics 20:603–615PubMed
48.
go back to reference Office of the Federal Register, National Archives and Records Administration (2001) Federal Register 66:40077–40102 Office of the Federal Register, National Archives and Records Administration (2001) Federal Register 66:40077–40102
49.
go back to reference Ortega A, Dranitsaris G, Puodziunas AL (1998) What are cancer patients willing to pay for prophylactic epoetin alfa? A cost benefit analysis. Cancer 83:2588–2596CrossRefPubMed Ortega A, Dranitsaris G, Puodziunas AL (1998) What are cancer patients willing to pay for prophylactic epoetin alfa? A cost benefit analysis. Cancer 83:2588–2596CrossRefPubMed
50.
go back to reference Peterman A, Cella D, Glandon G, Dobrez D, Yount S (2001) Mucositis in head and neck cancer: economic and quality-of-life outcomes. J Natl Cancer Inst Monogr 29:45–51PubMed Peterman A, Cella D, Glandon G, Dobrez D, Yount S (2001) Mucositis in head and neck cancer: economic and quality-of-life outcomes. J Natl Cancer Inst Monogr 29:45–51PubMed
51.
go back to reference Ruchlin HS, Dasbach EJ (2001) An economic overview of chronic obstructive pulmonary disease. Pharmacoeconomics 19:623–642PubMed Ruchlin HS, Dasbach EJ (2001) An economic overview of chronic obstructive pulmonary disease. Pharmacoeconomics 19:623–642PubMed
52.
go back to reference Sheffield R, Sullivan SD, Saltiel E, et al (1997) Cost comparison of recombinant human erythropoietin and blood transfusion in cancer chemotherapy-induced anemia. Ann Pharmacother 31:15–22PubMed Sheffield R, Sullivan SD, Saltiel E, et al (1997) Cost comparison of recombinant human erythropoietin and blood transfusion in cancer chemotherapy-induced anemia. Ann Pharmacother 31:15–22PubMed
53.
go back to reference Shulkin DJ, Kinosian B, Glick H, Glen-Puschett C, et al (1993) The economic impact of infections. An analysis of hospital costs and charges in surgical patients with cancer. Arch Surg 128:449–452PubMed Shulkin DJ, Kinosian B, Glick H, Glen-Puschett C, et al (1993) The economic impact of infections. An analysis of hospital costs and charges in surgical patients with cancer. Arch Surg 128:449–452PubMed
54.
go back to reference Sonis ST, Oster G, Fuchs H, Bellm L, Bradford WZ, Edelsberg J, et al (2001) Oral mucositis and the clinical and economic outcomes of hematopoietic stem-cell transplantation. J Clin Oncol 19:2201–2205PubMed Sonis ST, Oster G, Fuchs H, Bellm L, Bradford WZ, Edelsberg J, et al (2001) Oral mucositis and the clinical and economic outcomes of hematopoietic stem-cell transplantation. J Clin Oncol 19:2201–2205PubMed
55.
go back to reference Stewart DJ, Dahrouge S, Coyle D, Evans WK (1999) Costs of treating and preventing nausea and vomiting in patients receiving chemotherapy. J Clin Oncol 17:344–351PubMed Stewart DJ, Dahrouge S, Coyle D, Evans WK (1999) Costs of treating and preventing nausea and vomiting in patients receiving chemotherapy. J Clin Oncol 17:344–351PubMed
56.
go back to reference Sullivan SD, Ramsey SD, Lee TA (2000) The economic burden of COPD. Chest 117 [2 Suppl]:5S–9S Sullivan SD, Ramsey SD, Lee TA (2000) The economic burden of COPD. Chest 117 [2 Suppl]:5S–9S
57.
go back to reference Torrance G, Walker V, Grossman R, Mukherjee J, Vaughan D, LaForge J, Lampron N (1999) Economic evaluation of ciprofloxacin compared with usual antibacterial care for the treatment of acute exacerbations of chronic bronchitis in patients followed for 1 year. Pharmacoeconomics 16:499–520PubMed Torrance G, Walker V, Grossman R, Mukherjee J, Vaughan D, LaForge J, Lampron N (1999) Economic evaluation of ciprofloxacin compared with usual antibacterial care for the treatment of acute exacerbations of chronic bronchitis in patients followed for 1 year. Pharmacoeconomics 16:499–520PubMed
58.
go back to reference Turini M, Redaelli A, Gramegna P, Radice D (2003) Quality of life and economic considerations in the management of prostate cancer. Pharmacoeconomics 21:527–541PubMed Turini M, Redaelli A, Gramegna P, Radice D (2003) Quality of life and economic considerations in the management of prostate cancer. Pharmacoeconomics 21:527–541PubMed
59.
go back to reference Uyl-de Groot CA, Vellenga E, de Vries EGE, Lőwenberg B, et al (1997) Treatment costs and quality of life with granulocyte-macrophage colony-stimulating factor in patients with antineoplastic therapy-related febrile neutropenia. Pharmacoeconomics 12:351–360PubMed Uyl-de Groot CA, Vellenga E, de Vries EGE, Lőwenberg B, et al (1997) Treatment costs and quality of life with granulocyte-macrophage colony-stimulating factor in patients with antineoplastic therapy-related febrile neutropenia. Pharmacoeconomics 12:351–360PubMed
60.
go back to reference Wahlqvist P, Junghard O, Higgins A, Green J (2002) Cost effectiveness of esomeprazole compared with omeprazole in the acute treatment of patients with reflux oesophagitis in the UK. Pharmacoeconomics 20:279–287PubMed Wahlqvist P, Junghard O, Higgins A, Green J (2002) Cost effectiveness of esomeprazole compared with omeprazole in the acute treatment of patients with reflux oesophagitis in the UK. Pharmacoeconomics 20:279–287PubMed
61.
go back to reference Wang ECY, Grasela TH, Walawander CA (1999) Applying epidemiology-based outcomes research to clinical decision-making: a hypothetical model of biotechnology therapy in gram-negative sepsis. Pharmacoeconomics 15:385–393PubMed Wang ECY, Grasela TH, Walawander CA (1999) Applying epidemiology-based outcomes research to clinical decision-making: a hypothetical model of biotechnology therapy in gram-negative sepsis. Pharmacoeconomics 15:385–393PubMed
62.
go back to reference Ward MM, Javitz HS, Smith WM, et al (2000) Direct medical cost of chronic obstructive pulmonary disease in the U.S.A. Respir Med 94:1123–1129CrossRefPubMed Ward MM, Javitz HS, Smith WM, et al (2000) Direct medical cost of chronic obstructive pulmonary disease in the U.S.A. Respir Med 94:1123–1129CrossRefPubMed
63.
go back to reference Weimar C, Weber C, Wagner M, Busse O, et al (2003) Management patterns and health care use after intracerebral hemorrhage: a cost-of-illness study from a societal perspective in Germany. Cerebrovasc Dis 15:29–36CrossRef Weimar C, Weber C, Wagner M, Busse O, et al (2003) Management patterns and health care use after intracerebral hemorrhage: a cost-of-illness study from a societal perspective in Germany. Cerebrovasc Dis 15:29–36CrossRef
64.
go back to reference Wilson L, Devine EB, So K (2000) Direct medical costs of chronic obstructive pulmonary disease: chronic bronchitis and emphysema. Respir Med 94:204–213CrossRefPubMed Wilson L, Devine EB, So K (2000) Direct medical costs of chronic obstructive pulmonary disease: chronic bronchitis and emphysema. Respir Med 94:204–213CrossRefPubMed
65.
go back to reference Zabinski RA, Burke TA, Johnson J, Lavoie F, Fitzsimon C, Tretiak R, Chancellor JVM (2001) An economic model for determining the costs and consequences of using various treatment alternatives for the management of arthritis in Canada. Pharmacoeconomics 19 [Suppl 1]:49–58 Zabinski RA, Burke TA, Johnson J, Lavoie F, Fitzsimon C, Tretiak R, Chancellor JVM (2001) An economic model for determining the costs and consequences of using various treatment alternatives for the management of arthritis in Canada. Pharmacoeconomics 19 [Suppl 1]:49–58
Metadata
Title
The economic burden of supportive care of cancer patients
Authors
Linda S. Elting
Ya-Chen Tina Shih
Publication date
01-04-2004
Publisher
Springer-Verlag
Published in
Supportive Care in Cancer / Issue 4/2004
Print ISSN: 0941-4355
Electronic ISSN: 1433-7339
DOI
https://doi.org/10.1007/s00520-003-0513-1

Other articles of this Issue 4/2004

Supportive Care in Cancer 4/2004 Go to the issue

Society News

April 2004

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine